Expert Perspectives on Advances in the Management of C. difficile - Episode 18

Making Strides in the Management of C. Difficile

Therapies in the pipeline to treat C. difficile and closing thoughts on what is most exciting, in regards to better prevention and management of the condition, moving forward.

EP. 1: C. Difficile Risk Factors and Manifestation
EP. 2: Strains of C. Difficile
EP. 3: Managing Community-Onset C. Difficile
EP. 4: Recurrent C. Difficile
EP. 5: C. Difficile: A Differential Diagnosis
EP. 6: Testing for C. Difficile Infections
EP. 7: Screening for C. Difficile
EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options
EP. 9: C. Difficile: Updates to Clinical Practice Guidelines
EP. 10: Selecting Therapy to Treat C. Difficile
EP. 11: C. Difficile Treatment: Fidaxomicin
EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
EP. 13: C. Difficile Treatment: Bezlotoxumab
EP. 14: Preventing/Treating C. Difficile: Unmet Needs
EP. 15: Fecal Microbiota Transplantation for C. Difficile Infections
EP. 16: Emerging Treatment Options for C. Difficile Infections
EP. 17: C. Difficile: Barriers Treating With FMT
Now Viewing
EP. 18: Making Strides in the Management of C. Difficile

Related Content:

Expert Perspectives on Advances in the Management of C. difficileC. DIFFICILEGASTROINTESTINAL INFECTIONS
How Did COVID-19 Affect Clostridioides Difficile Testing and Incidence Rates?
Stem Cell Patients with C Difficile Benefit from Vancomycin, Fidaxomicin
Investigational Clostridioides Difficile Therapy Demonstrates Superiority Over Placebo